A recent study has examined the characteristics and the clinical outcomes for individuals with severe anti-neutrophil cytoplasmic antibody-associated vasculitides (AAVs). AAVs are a very rare group of systemic autoimmune conditions.…
Sometimes, certain drugs may be approved in different countries and not in others. However, drug approval spanning multiple countries highlights the importance of getting drugs and treatments into the hands…
According to ANCA Vasculitis News, the FDA recently approved Riabni (rituximab-arrx) for the treatment of adult patients with two specific subtypes of ANCA vasculitis: microscopic polyangiitis (MPA) and granulomatosis with…
According to a story from ANCA Vasculitis News, a recent study has determined that monitoring changes in autoantibodies targeting the PR3 protein is useful for predicting ANCA vasculitis remission after…
Recently, the American College of Rheumatology (ACR) virtually held ACR Convergence 2020, the organization's annual meeting. At the meeting, researchers shared new insights in the realm of rheumatology; these were…
On November 3, 2020, biopharmaceutical company ChemoCentryx and global pharmaceutical company Vifor Pharma Group's sub-business Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that the European Medicines Agency will review…
According to a story from GlobeNewswire, Exagen, Inc. recently launched a testing panel called AVISE® Vasculitis AAV, which is designed to help physicians get fast and accurate data for patients…
In a recent press release, biopharmaceutical company ChemoCentryx announced FDA approval for a New Drug Application (NDA) for avacopan, a treatment for ANCA-associated vasculitis. According to the FDA, a New…
According to a story from finanzen.ch, the US Food and Drug Administration (FDA) recently approved the drug rituximab (marketed as Rituxan) as a treatment in child patients aged at least…
The FDA announced last week that it has approved Rituxan (rituximab)to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination…
According to a story from ANCA Vasculitis News, a recent study from Spain is highlighting the need for an updated classification system for ANCA-associated vasculitis that can predict patient prognosis…
According to a story from Bronchiectasis News Today, the results of a new study suggests that bronchiectasis may trigger autoimmune inflammatory disease. The study found that the condition was frequently…
Okay, here's what's terrifying to me—the fact that there are SO many rare diseases out there and science hasn't even begun to skim the surface of knowing how and when…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
